MENU
+Compare
JAGX
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$0.86
Change
-$0.02 (-2.27%)
Capitalization
11.2M

JAGX Jaguar Health Inc. Forecast, Technical & Fundamental Analysis

a developer of pharmaceuticals

Industry Biotechnology
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for JAGX with price predictions
Feb 21, 2025

JAGX in +14.46% Uptrend, advancing for three consecutive days on February 19, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where JAGX advanced for three days, in of 189 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 14, 2025. You may want to consider a long position or call options on JAGX as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for JAGX just turned positive on February 13, 2025. Looking at past instances where JAGX's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 24 cases where JAGX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

JAGX moved below its 50-day moving average on February 20, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for JAGX crossed bearishly below the 50-day moving average on January 21, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JAGX broke above its upper Bollinger Band on February 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.823) is normal, around the industry mean (12.496). P/E Ratio (0.042) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). JAGX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.375) is also within normal values, averaging (251.218).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JAGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Generic
Address
200 Pine Street
Phone
+1 415 371-8300
Employees
49
Web
http://www.jaguar.health
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ACU37.06-0.48
-1.28%
Acme United Corp
RPM121.19-1.96
-1.59%
RPM International
EMBC14.10-0.31
-2.15%
Embecta Corp
MEOH44.25-1.44
-3.15%
Methanex Corp
OLB1.26-0.04
-3.45%
OLB Group Inc. (The)

JAGX and Stocks

Correlation & Price change

A.I.dvisor tells us that JAGX and HEPA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and HEPA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-2.86%
HEPA - JAGX
29%
Poorly correlated
-9.20%
VXRT - JAGX
28%
Poorly correlated
+1.21%
DVHGF - JAGX
27%
Poorly correlated
+54.55%
AFMD - JAGX
26%
Poorly correlated
+1.96%
SNPX - JAGX
26%
Poorly correlated
+1.06%
More